ReviewFrontiers in neurology2023
Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities.
Review in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Digital Biomarkers for the Assessment of Non-Cognitive Symptoms in Patients with Dementia with Lewy Bodies: A Systematic Review.Journal of Alzheimer's disease : JAD · 2024Pooled it
- A digitally supported multimodal lifestyle program to promote brain health among older adults (the LETHE randomized controlled feasibility trial): study design, progress, and first results.Alzheimer's research & therapy · 2024Trial
- Longitudinal Cognitive Function in Progressive Supranuclear Palsy-A Review of the Evidence for Progression.Movement disorders clinical practice · 2026Review
- Powering Neurology Drug Development Trials to Reduce False Negative Results.Clinical and translational science · 2026Review
- Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Enhancing Early Diagnosis: Multimodal AI Approaches for Neurodegenerative Diseases.Journal of biotechnology and biomedicine · 2026Article
- Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases.Frontiers in digital health · 2026Article
- Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review.NPJ digital medicine · 2025Article
- Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development.NPJ digital medicine · 2025Article
- Using wearable sensors and machine learning to assess upper limb function in Huntington's disease.Communications medicine · 2025Article
- Informed consent in dementia research: how Public Involvement can contribute to addressing "old" and "new" challenges.Frontiers in dementia · 2025Article
- The SLaM Brain Health Clinic: remote biomarker enhanced memory clinic for people with mild cognitive impairment within a National Health Service mental health trust.BJPsych open · 2024Article
- Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop.Journal of Parkinson's disease · 2024Review
- Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.NPJ digital medicine · 2024Article
- A wearable sensor and machine learning estimate step length in older adults and patients with neurological disorders.NPJ digital medicine · 2024Article
- Accuracy, concurrent validity, and test-retest reliability of pressure-based insoles for gait measurement in chronic stroke patients.Frontiers in digital health · 2024Article
- Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort.The journal of prevention of Alzheimer's disease · 2024Review
- Assessing the cognitive decline of people in the spectrum of AD by monitoring their activities of daily living in an IoT-enabled smart home environment: a cross-sectional pilot study.Frontiers in aging neuroscience · 2024Article
- Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change.Alzheimer's & dementia (New York, N. Y.)Article
- Research Landscapes and Gaps in Neuropsychiatric Assessment for Neurodegenerative Diseases: A Bibliometric Study on Huntington's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) and other neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's disease (HD) are associated with progressive cognitive, motor, affective and consequently functional decline considerably affecting Activities of Daily Living (ADL) and quality of life. Standard assessments, such as questionnaires and interviews, cognitive testing, and mobility assessments, lack sensitivity, especially in early stages of neurodegenerative diseases and in the disease progression, and have therefore a limited utility as outcome measurements in clinical trials. Major advances in the last decade in digital technologies have opened a window of opportunity to introduce digital endpoints into clinical trials that can reform the assessment and tracking of neurodegenerative symptoms. The Innovative Health Initiative (IMI)-funded projects RADAR-AD (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.